LGBTQ Nation on MSN
U.S. ships groundbreaking HIV drug to Africa, but slashed funding threatens progress
The U.S. just shipped two million doses of lenacapavir, a groundbreaking twice-a-year HIV-prevention injectable medication, ...
Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...
Zacks Investment Research on MSN
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
Merck MRK announced positive top-line results from a pivotal late-stage study evaluating its investigational, once-daily, ...
Data from a new surveillance report show rising resistance to ceftriaxone and cefixime, the two antibiotics currently ...
Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.
Novo Nordisk is expected to announce soon whether its blockbuster GLP-1 drug semaglutide can help slow Alzheimer’s disease ...
The United States said Tuesday it has delivered a new treatment to prevent HIV in two African countries, months after President Donald Trump dramatically cut global aid.
Eswatini has become the first African country to receive lenacapavir, a twice-yearly HIV prevention injection that global ...
3d
NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position
NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2025 with the Securities and Exchange ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback